Celyad Oncology SA announced that it expects to receive 28.73 million in funding from Fortress Investment Group LLC
Celyad Oncology SA announced that it has entered into a subscription agreement with an affiliate of Fortress Investment Group LLC for private placement of 6,500,000 shares at an issue price of 4.42 per share for gross proceeds of 28,730,000 on December 3, 2021. The transaction is expected to close on or about December 8, 2021, subject to satisfaction of customary closing conditions. Post-closing of transaction, investor will hold 28.8% of the companys shares. The shares are subject to hold period.